第34届亚太肝病学会年会：多元合作为消除和治愈病毒性肝炎努力

Core Viewpoint - The 34th Asia-Pacific Association for the Study of the Liver (APASL) conference focused on "Diverse Cooperation: Creating Miracles of Elimination and Cure," emphasizing the breakthrough value of "functional cure" for hepatitis B [1] Group 1: Achievements in Hepatitis Prevention and Control - China has integrated the prevention and control of major infectious diseases, including hepatitis B, into the "Healthy China 2030 Planning Outline" [2] - The hepatitis B virus carrier rate in China has decreased from 9.72% in 1992 to 5.86%, with the rate among children under 5 dropping over 96% from 9.67% to 0.30%, achieving the target set for 2030 ahead of schedule [2] Group 2: Systematic Approach to Hepatitis Management - The success in hepatitis prevention and control in China is attributed to national top-level design, optimized prevention measures, advancements in biomedical technology, and a solid foundation of community-based prevention [3] - Continuous optimization of chronic hepatitis management strategies is essential to achieve the goals of the "Healthy China 2030" initiative [3] Group 3: Focus on Functional Cure - "Functional cure" is defined as the absence of detectable hepatitis B virus and surface antigen in the blood after stopping treatment, significantly improving patients' quality of life [4] - Traditional antiviral treatments have struggled to achieve the disappearance of hepatitis B surface antigen, leading to long-term treatment burdens for patients [4] - The National Medical Products Administration of China has issued guidelines emphasizing "functional cure" as a key endpoint for new drug development in chronic hepatitis B treatment [4]